what is the difference between wegovy and semaglutide Pills vs Shots: Which More Effective? Wegovy vs. Ozempic: What To

Use only after consulting a doctor or specialist

Clinical trials are actively investigating GLP-1 Drugs for conditions like cardiovascular disease and liver disorders, with first approvals expected by 2025

Key findings Within six months of starting GLP-1 therapy, the rate of hypotensive events increased from 8.7% to 10.2% The increased risk remained significant at 12 months, with hypotensive events rising from 13.6% to 14.3% Adults age 65 and older accounted for 53% of hypotensive events despite representing 37% of the study population Patients with Type 2 diabetes made up 75% of those experiencing hypotensive episodes but only 63% of the overall cohort In secondary analyses, the scientists found that weight loss alone did not explain the increased risk, suggesting other mechanisms of action may be at play Below is a Q&A with study senior author Dr

Reintroducing semaglutide after a longer gap may cause stronger initial side effects as your system readjusts

L-

These benefits occur independently of significant weight loss, meaning a patient with normal BMI but prior heart attack or stroke may qualify for semaglutide or tirzepatide for cardioprotection